# A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

> **NCT06244771** · PHASE1,PHASE2 · RECRUITING · sponsor: **Frontier Medicines Corporation** · enrollment: 403 (estimated)

## Conditions studied

- Advanced Solid Tumors With KRAS G12C Mutations
- Solid Tumor, Adult
- Unresectable Solid Tumor
- Metastatic Solid Tumor
- Non Small Cell Lung Cancer
- Colorectal Cancer
- KRAS G12C
- Pancreatic Cancer

## Interventions

- **DRUG:** FMC-376

## Key facts

- **NCT ID:** NCT06244771
- **Lead sponsor:** Frontier Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-12
- **Primary completion:** 2027-10
- **Final completion:** 2028-04
- **Target enrollment:** 403 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06244771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06244771, "A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06244771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*